GB201218862D0 - Bicyclic heterocycle compounds and their uses in therapy - Google Patents

Bicyclic heterocycle compounds and their uses in therapy

Info

Publication number
GB201218862D0
GB201218862D0 GBGB1218862.9A GB201218862A GB201218862D0 GB 201218862 D0 GB201218862 D0 GB 201218862D0 GB 201218862 A GB201218862 A GB 201218862A GB 201218862 D0 GB201218862 D0 GB 201218862D0
Authority
GB
United Kingdom
Prior art keywords
therapy
bicyclic heterocycle
heterocycle compounds
compounds
bicyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1218862.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Therapeutics Ltd
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Priority to GBGB1218862.9A priority Critical patent/GB201218862D0/en
Publication of GB201218862D0 publication Critical patent/GB201218862D0/en
Priority to JP2015537354A priority patent/JP6381534B2/ja
Priority to CA2888107A priority patent/CA2888107C/en
Priority to PCT/GB2013/052720 priority patent/WO2014060767A1/en
Priority to US14/436,345 priority patent/US9617283B2/en
Priority to KR1020157012696A priority patent/KR102299834B1/ko
Priority to ES13780387T priority patent/ES2847897T3/es
Priority to EP13780387.0A priority patent/EP2909196B1/en
Priority to CN201380066428.XA priority patent/CN104870441B/zh
Priority to DK13780387.0T priority patent/DK2909196T3/da
Priority to US15/411,463 priority patent/US9980973B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
GBGB1218862.9A 2012-10-19 2012-10-19 Bicyclic heterocycle compounds and their uses in therapy Ceased GB201218862D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB1218862.9A GB201218862D0 (en) 2012-10-19 2012-10-19 Bicyclic heterocycle compounds and their uses in therapy
DK13780387.0T DK2909196T3 (da) 2012-10-19 2013-10-18 Bicykliske heterocykliske forbindelser og anvendelser deraf ved terapi
US14/436,345 US9617283B2 (en) 2012-10-19 2013-10-18 Bicyclic heterocycle compounds and their uses in therapy
CA2888107A CA2888107C (en) 2012-10-19 2013-10-18 Bicyclic heterocycle compounds and their uses in therapy
PCT/GB2013/052720 WO2014060767A1 (en) 2012-10-19 2013-10-18 Bicyclic heterocycle compounds and their uses in therapy
JP2015537354A JP6381534B2 (ja) 2012-10-19 2013-10-18 二環式複素環化合物およびそれらの治療での使用
KR1020157012696A KR102299834B1 (ko) 2012-10-19 2013-10-18 바이사이클릭 헤테로사이클 화합물 및 치료에서의 그것의 용도
ES13780387T ES2847897T3 (es) 2012-10-19 2013-10-18 Compuestos heterocíclicos bicíclicos y sus usos en terapia
EP13780387.0A EP2909196B1 (en) 2012-10-19 2013-10-18 Bicyclic heterocycle compounds and their uses in therapy
CN201380066428.XA CN104870441B (zh) 2012-10-19 2013-10-18 双环杂环化合物及其治疗用途
US15/411,463 US9980973B2 (en) 2012-10-19 2017-01-20 Bicyclic heterocycle compounds and their uses in therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1218862.9A GB201218862D0 (en) 2012-10-19 2012-10-19 Bicyclic heterocycle compounds and their uses in therapy

Publications (1)

Publication Number Publication Date
GB201218862D0 true GB201218862D0 (en) 2012-12-05

Family

ID=47359189

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1218862.9A Ceased GB201218862D0 (en) 2012-10-19 2012-10-19 Bicyclic heterocycle compounds and their uses in therapy

Country Status (10)

Country Link
US (1) US9617283B2 (OSRAM)
EP (1) EP2909196B1 (OSRAM)
JP (1) JP6381534B2 (OSRAM)
KR (1) KR102299834B1 (OSRAM)
CN (1) CN104870441B (OSRAM)
CA (1) CA2888107C (OSRAM)
DK (1) DK2909196T3 (OSRAM)
ES (1) ES2847897T3 (OSRAM)
GB (1) GB201218862D0 (OSRAM)
WO (1) WO2014060767A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
ES2883289T3 (es) * 2013-12-20 2021-12-07 Astex Therapeutics Ltd Compuestos heterocíclicos bicíclicos y sus usos en terapia
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
US10781205B2 (en) 2016-04-20 2020-09-22 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
EP3455221B1 (en) * 2016-05-09 2020-03-11 H. Hoffnabb-La Roche Ag Dimeric compounds
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
CN106265764B (zh) 2016-08-18 2018-03-16 广州威溶特医药科技有限公司 Iap抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
CN109535070B (zh) * 2018-12-27 2022-03-29 青岛清原化合物有限公司 吡啶氧基羧酸酯衍生物及其制备方法、除草组合物和应用
BR112021012415B1 (pt) 2018-12-27 2024-02-15 Qingdao Kingagroot Chemical Compound Co., Ltd Derivado de piridiloxicarboxilato, composição herbicida compreendendo o mesmo, método para preparar o mesmo, bem como método e uso do dito derivado para controlar erva daninha
EP3947368B1 (en) 2019-04-04 2025-09-03 Dana-Farber Cancer Institute, Inc. Bifunctional compounds comprising a cdk2/5 ligand, a linker and a e3 ubiquitin ligase binding degron for the treatment of cancer
CA3148504A1 (en) 2019-08-08 2021-02-11 Institute For Cancer Research D/B/A/ The Research Institute Of Fox Chase Cancer Center Combination therapy for treatment of cancer
CN110483509B (zh) * 2019-09-04 2020-08-25 温州大学 一种合成含氮杂环衍生物的方法
CN110627785B (zh) * 2019-09-19 2021-06-25 温州大学 一种1,5-四氢萘啶衍生物的制备方法
CN120247907A (zh) * 2020-05-04 2025-07-04 大塚制药株式会社 Iap拮抗剂化合物和中间体及其合成方法
EP4161937A4 (en) * 2020-06-04 2024-06-12 BeiGene, Ltd. PYRIDO[2, 3-B] [1, 4] OXAZINES OR TETRAHYDROPYRIDO [2, 3-B] [1, 4] OXAZEPINES USED AS IAP ANTAGONISTS
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN116731016A (zh) * 2022-03-11 2023-09-12 苏州亚盛药业有限公司 作为iap拮抗剂的三环杂环化合物
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080330A (en) 1975-06-23 1978-03-21 Delmar Chemicals Limited Phenylindolines and process for their production
DE3822792C2 (de) 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
TW218875B (OSRAM) 1992-03-09 1994-01-11 Takeda Pharm Industry Co Ltd
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
EP0778277B1 (en) 1995-12-08 2003-06-25 Pfizer Inc. Substituted heterocyclic derivatives as CRF antagonists
DK0892780T3 (da) 1996-02-22 2003-03-03 Bristol Myers Squibb Pharma Co m-Amidinophenylanaloger som faktor Xa-inhibitorer
EP0944388A4 (en) 1996-04-03 2001-08-16 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
AU719102B2 (en) 1996-06-28 2000-05-04 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2001524116A (ja) 1997-04-18 2001-11-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つインドール誘導体
US6084098A (en) 1999-02-26 2000-07-04 Neurogen Corporation Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands
WO1999050247A1 (en) 1998-03-31 1999-10-07 Acadia Pharmaceuticals, Inc. Compounds with activity on muscarinic receptors
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6608084B1 (en) 1998-08-26 2003-08-19 Aventis Pharma Ltd. Aza-bicycles which modulate the inhibition of cell adhesion
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
AU3555200A (en) 1999-03-17 2000-10-04 F. Hoffmann-La Roche Ag Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators
GB9929552D0 (en) 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
WO2001012600A1 (en) 1999-08-12 2001-02-22 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
ATE399753T1 (de) 1999-09-04 2008-07-15 Astrazeneca Ab Amide als pyruvatdehydrogenaseinhibitoren
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
CA2433090A1 (en) 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
AU2002303264A1 (en) 2001-04-09 2002-10-21 Bristol-Myers Squibb Company Fused heterocyclic inhibitors of factor xa
JP2004534017A (ja) 2001-04-27 2004-11-11 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｂａｃｅのインヒビター
AU2003235097A1 (en) 2002-04-24 2003-11-10 Takeda Pharmaceutical Company Limited Use of compounds having ccr antagonism
BRPI0408136A (pt) 2003-03-07 2006-03-01 Astellas Pharma Inc derivados heterocìclicos contendo nitrogênio tendo estirila 2,6-dissubstituìda
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
US7514438B2 (en) 2003-08-13 2009-04-07 Amgen, Inc. Melanin concentrating hormone receptor antagonist
TW200524887A (en) 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
US7674787B2 (en) 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
WO2006032987A1 (en) 2004-09-23 2006-03-30 Pfizer Products Inc. Indoline compounds and their use in the treatment of arteriosclerosis
ATE477254T1 (de) 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
CN101128425B (zh) * 2005-02-25 2012-12-26 泰特拉洛吉克药业公司 Iap二聚体抑制剂
WO2007073405A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
FR2896504B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
GB0602335D0 (en) 2006-02-07 2006-03-15 Remynd Nv Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
WO2008014252A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Iap inhibitors
US8044209B2 (en) * 2006-10-12 2011-10-25 Novartis Ag Pyrrolydine derivatives as IAP inhibitors
PT2099769E (pt) * 2006-12-07 2012-08-31 Novartis Ag 6-oxo-1,6-di-hidropirimidin-2-ilos no tratamento de doenças proliferativas
CA2680312A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
KR20100119768A (ko) * 2008-01-24 2010-11-10 테트랄로직 파마슈티칼스 코포레이션 아이에이피 억제제
WO2009147476A1 (en) 2008-06-02 2009-12-10 Matrix Laboratories Ltd. Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation
US9174969B2 (en) 2008-07-21 2015-11-03 University Of South Florida Indoline scaffold SHP-2 inhibitors and cancer treatment method
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
WO2010121212A2 (en) 2009-04-17 2010-10-21 H. Lee Moffit Cancer Center And Research Institute, Inc. Indoline scaffold shp-2 inhibitors and method of treating cancer
MX2011011735A (es) 2009-05-04 2011-11-29 Plexxikon Inc Compuestos y metodos para la inhibicion de renina, e indicaciones para ello.
WO2010138666A1 (en) 2009-05-28 2010-12-02 Tetralogic Pharmaceuticals Corp. Iap inhibitors
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
US9499479B2 (en) 2011-10-03 2016-11-22 The Trustees Of Columbia University In The City Of New York Molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
PL2800738T3 (pl) 2012-01-06 2020-10-19 Novartis Ag Związki heterocykliczne i sposoby ich stosowania
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
ES2883289T3 (es) 2013-12-20 2021-12-07 Astex Therapeutics Ltd Compuestos heterocíclicos bicíclicos y sus usos en terapia
JP6510539B2 (ja) 2014-01-09 2019-05-08 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン 置換ベンゾオキサジン及び関連化合物

Also Published As

Publication number Publication date
CN104870441A (zh) 2015-08-26
EP2909196A1 (en) 2015-08-26
CN104870441B (zh) 2017-09-29
CA2888107C (en) 2023-10-31
WO2014060767A1 (en) 2014-04-24
JP6381534B2 (ja) 2018-08-29
CA2888107A1 (en) 2014-04-24
KR20150072435A (ko) 2015-06-29
US20150259359A1 (en) 2015-09-17
ES2847897T3 (es) 2021-08-04
US9617283B2 (en) 2017-04-11
DK2909196T3 (da) 2021-03-01
KR102299834B1 (ko) 2021-09-07
JP2016500684A (ja) 2016-01-14
EP2909196B1 (en) 2020-12-02

Similar Documents

Publication Publication Date Title
GB201218862D0 (en) Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) Bicyclic heterocycle compounds and their uses in therapy
ZA201307797B (en) Bicyclic heterocycle compounds and their uses in therapy
IL246239A0 (en) Bicyclic heterocyclic compounds and their uses in healing
GB201218864D0 (en) Bicyclic heterocycle compounds and their uses in therapy
IL234628A0 (en) Imidazolyl-pyrimidines are converted into amino-indolyl and their use as drugs
IL238400A (en) Triazulophyrazines as brd4 inhibitors for use in cancer treatment
GB201120993D0 (en) Novel compounds and their use in therapy
EP2867209A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USES
SG11201502317VA (en) Telomerase inhibitors for use in therapy
ZA201504405B (en) 6-chloro-3-(phenyl-d5)-inden-1-one and use thereof
IL238453A0 (en) Trans-clomiphene for use in cancer treatment
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
PT2875026T (pt) Derivados de imidazopiridina utilizados no tratamento da diabetes
LT2872176T (lt) Karboranilporfirinai, skirti naudoti vėžio gydymui
GB201308753D0 (en) Compounds and their use in therapy
GB201308217D0 (en) Compounds and their use in therapy
GB201322755D0 (en) Bicyclic heterocycle compounds and their uses in therapy
HK1230598A1 (en) Bicyclic heterocycle compounds and their uses in therapy
HK1189597A (en) Bicyclic heterocycle compounds and their uses in therapy
GB201223371D0 (en) Novel mucinase for use in therapy or prophylaxis
ME03635B (me) 6-hlor0-3-(fenil-d5)-inden-1-on i njegova upotreba
GB201214454D0 (en) Therapeutic treatments
GB201214456D0 (en) Therapeutic treatments

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)